CRO Services - ACTG-CRO
Bioequivalence studies are required for the Market Authorization Submission in Tunisia and african countries from Pharmaceutical companies producing generics who want to have the medicines distributed and sold in the african continent.
At ACTG-CRO, we provide you a dedicated Bioequivalence Site Partner WHO certified to run your studies under our supervision and management for a successful result.
Our Site Partner is a WHO-ACCREDITed AND CLEARED USFDA WITH NIL 483Bioequivalence Center
With ACTG-CRO, your Company receives the results and reports of your Bioequivalence Studies within 60 days once our Center Partner receives the reference products.